Skip to main content

Table 1 Cohort demographic and clinical characteristics

From: GluN2B protein deficits in the left, but not the right, hippocampus in schizophrenia

Variable Cohort Control Schizophrenia t p
n Western Blot 20 20   
Receptor binding 21 20   
Age at death Western Blot 54.5 ± 13.4 (24-73) 54.7 ± 12.8 (27-75) -0.036 0.971
  Mean years ± SD (range) Receptor binding 55.3 ± 13.1 (24-73) 54.8 ± 12.8 (27-75) 0.132 0.895
Post-mortem interval Western Blot 28.2 ± 13.3 29.5 ± 12.5 -0.307 0.761
  Mean hours ± SD Receptor binding 30.5 ± 13.6 28.9 ± 12.3 0.388 0.700
pH Western Blot 6.47 ± 0.35 6.47 ± 0.16 0.069 0.945
  Mean ± SD Receptor binding 6.44 ± 0.35 6.47 ± 0.16 -0.381 0.706
Gender Western Blot 12 M/8 F 12 M/8 F N/A N/A
Receptor binding 12 M/9 F 12 M/8 F N/A N/A
Hemisphere Western Blot 10 L/10R 11 L/9R N/A N/A
Receptor binding 10 L/11R 10 L/10R N/A N/A
Brain weight Western Blot 1410 ± 128 1358 ± 172 1.085 0.285
  Mean grams ± SD Receptor binding 1396 ± 139 1358 ± 172 0.792 0.433
Estimated daily antipsychotic drug dose Western Blot N/A 782 ± 543 N/A N/A
  Mean CPZ equiv ± SD Receptor binding N/A 809 ± 529 N/A N/A
Age of onset Western Blot N/A 24.1 ± 8.2 (14-44) N/A N/A
  Mean years ± SD (range) Receptor binding N/A 23.6 ± 8.1 (14-44) N/A N/A
Duration of illness Western Blot N/A 30.6 ± 11.9 (12-47) N/A N/A
  Mean years ± SD (range) Receptor binding N/A 30.7 ± 11.9 (12-47) N/A N/A
  1. There was an overlap of 84% (37/44) between subjects included in the western blot and receptor binding studies. Independent t-tests show no significant differences in age at death, post-mortem interval, pH or brain weight between schizophrenia and control groups; Abbreviations: M, male; F, female; L, left; R, right; PMI, post-mortem interval; CPZ equiv, chlorpromazine equivalents. N/A, not applicable.